drugset / Trial / NCT07188558
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Timeline
- Start
- 2026-01-12
- Primary completion
- 2029-12
- Completion
- 2032-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Axicabtagene Ciloleucel | Cell therapy | — | Intravenous |
| Comparator | Lisocabtagene Maraleucel | Cell therapy | — | Intravenous |
| Subject | Rondecabtagene autoleucel | Cell therapy | — | Intravenous |